Feb. 10, 2021 16:09 UTC
PARIS--(BUSINESS WIRE)-- WhiteLab Genomics, a specialist in artificial intelligence applied to gene and cell therapies, has signed a partnership agreement with Genethon, a pioneering research center in the field of gene therapy.The alliance will harness the power of artificial intelligence to accelerate development of innovative gene therapies.
As part of this partnership, Genethon teams will use WhiteLab Genomics CatalystTM platform to develop new capsids, or vectors, which are essential components for gene therapy products.
While several gene therapy products have already obtained market authorization for the treatment of rare and common diseases, which demonstrates the efficacy of this approach for conditions considered to be incurable, development of these complex therapies continues to face major scientific and technical hurdles. Many vectors used in gene therapy are derivatives of adeno-associated viruses (AAV). Their use has limitations: natural immunization of 30% to 40% of the population and difficulty targeting a specific tissue. As a result, extremely large quantities of vectors are necessary. In this context, the use of artificial intelligence solutions stands out as a deciding factor to overcome these obstacles and produce optimized vectors that better target the relevant tissues, thus making it possible to inject smaller quantities of product while maximizing the effect of the therapy.
Turning to AI for faster development of optimized vectors
Genethons teams will use WhiteLab Genomics CatalystTM platform to accelerate select research programs.
Thanks to its Machine Learning algorithms, the WhiteLab Genomics platform will help researchers develop next-generation gene therapy vectors, with a view to enhancing their precision with regard to the tissues to be treated while reducing their immunogenic qualities.
The tools developed by WhiteLab will make it possible for us to review thousands of sequences and devise new and innovative combinations. We aim to develop a new generation of more specific AAV vectors, contributing to the emergence of original treatments for neuromuscular disorders, said Dr. Ronzitti, who is managing the collaboration for Genethon.
We are thrilled to be working together with worldwide trailblazers and experts in the area of gene therapy, stated David Del Bourgo, CEO and co-founder of WhiteLab Genomics. France is a prime source of innovation in this field, and we look forward to helping research teams, in France and abroad, to make practical use of these extremely complex biological datasets, while also providing assistance to accelerate the development of optimized products.
About White Lab Genomics
Founded in 2019 by David Del Bourgo, Julien Cottineau and Lucia Cinque, WhiteLab Genomics is a French start-up specializing in artificial intelligence solutions dedicated to biotherapies, such as gene and cell therapies. The companys proprietary technology allows for multi-parameter analysis of complex biological data to optimize these treatments while reducing development costs. WhiteLab Genomics provides this unique technology to its clients via the Catalyst platform, available in SaaS mode. Today, the start-up has locations at the Evry Gnopole Frances first biocluster and at Station F. WhiteLab Genomics was recently ranked among Station Fs Future 40, an index of the 40 most promising companies within Europes largest start-up incubator. https://www.whitelabgx.com
About Genethon
Created by AFM-Telethon, Genethon is a non-profit research and development center dedicated to creating gene therapy products for rare diseases, from initial research to clinical validation. Genethon has several programs underway, in clinical, pre-clinical and research phases, to treat rare muscular, blood, immune system and liver disorders. Today, a product incorporating technologies developed thanks to Genethons pioneering research is available on the market in the United States, Europe and Japan to treat spinal muscular atrophy. Ten other products created through Genethon R&D, alone or in collaboration with partners, are at the clinical trial stage, while many more are slated to begin clinical trials in 2021 and 2022. Genethon.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005707/en/
Here is the original post:
- Difference Between Ex Vivo and In Vivo Gene Therapy - December 30th, 2022 [December 30th, 2022]
- Gene therapy: The Potential for Treating Type 1 Diabetes - Healthline - December 30th, 2022 [December 30th, 2022]
- Gene therapy | Description, Uses, Examples, & Safety Issues - December 30th, 2022 [December 30th, 2022]
- Cell and gene therapy: Biopharma portfolio strategy | McKinsey - December 30th, 2022 [December 30th, 2022]
- History of Gene Therapy | Discovery and Evolution - December 30th, 2022 [December 30th, 2022]
- What is Gene Therapy? | FDA - U.S. Food and Drug Administration - December 30th, 2022 [December 30th, 2022]
- Gene Therapy Gel Offers New Hope Against Rare Blistering Disease - December 30th, 2022 [December 30th, 2022]
- Fact Check-mRNA vaccines are distinct from gene therapy ... - Reuters - December 6th, 2022 [December 6th, 2022]
- New Treatments for Retinitis Pigmentosa - American Academy of ... - December 6th, 2022 [December 6th, 2022]
- The Era of One-Shot, Multimillion-Dollar Genetic Cures Is Here - WIRED - December 6th, 2022 [December 6th, 2022]
- Greta Thunberg Says UN Climate Conference Is a Scam and She's Not Attending - November 4th, 2022 [November 4th, 2022]
- This Deepfake AI Singing Dolly Parton's "Jolene" Is Worryingly Good - November 4th, 2022 [November 4th, 2022]
- There's Something Strange About How These Stars Are Moving, Scientists Say - November 4th, 2022 [November 4th, 2022]
- Manslaughter Case Has a Strange Twist: Tesla That Killed Couple Was on Autopilot - November 4th, 2022 [November 4th, 2022]
- Twitter Working on Plan to Charge Users to Watch Videos - November 4th, 2022 [November 4th, 2022]
- China Plans to Send Monkeys to Space Station to Have Sex With Each Other - November 4th, 2022 [November 4th, 2022]
- Elon Musk Meeting With Advertisers, Begging Them Not to Leave Twitter - November 4th, 2022 [November 4th, 2022]
- NASA Sets Launch Date for Mission to $10 Quintillion Asteroid - November 4th, 2022 [November 4th, 2022]
- Scientists Found a Way to Control How High Mice Got on Cocaine - November 4th, 2022 [November 4th, 2022]
- Cats May Be Tampering With Crime Scenes, Scientists Say - November 4th, 2022 [November 4th, 2022]
- Scientists Use Actual Lunar Soil Sample to Create Rocket Fuel - November 4th, 2022 [November 4th, 2022]
- Scientists Spot "Stripped, Pulsating Core" of Star Caused By Horrific Accident - November 4th, 2022 [November 4th, 2022]
- US Gov to Crack Down on "Bossware" That Spies On Employees' Computers - November 4th, 2022 [November 4th, 2022]
- AOC Says Her Twitter Account Broke After She Made Fun of Elon Musk - November 4th, 2022 [November 4th, 2022]
- Hackers Just Took Down One of the World's Most Advanced Telescopes - November 4th, 2022 [November 4th, 2022]
- Huge Drone Swarm to Form Giant Advertisement Over NYC Skyline - November 4th, 2022 [November 4th, 2022]
- Chinese Spaceplane Releases Mystery Object Into Orbit - November 4th, 2022 [November 4th, 2022]
- That "Research" About How Smartphones Are Causing Deformed Human Bodies Is SEO Spam, You Idiots - November 4th, 2022 [November 4th, 2022]
- Jeff Bezos' Housekeeper Says She Had to Climb Out the Window to Use the Bathroom - November 4th, 2022 [November 4th, 2022]
- Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership - PR Newswire - October 19th, 2022 [October 19th, 2022]
- Gene therapy can make a real impact on global health but we need equitable access, say experts - World Economic Forum - October 19th, 2022 [October 19th, 2022]
- Gene Therapy Has Arrived. But So Will the $$$$$ Bills. | AMCP Nexus 2022 - Managed Healthcare Executive - October 19th, 2022 [October 19th, 2022]
- Carmine Gets Series A Funding to Develop Non-viral Gene Therapy |... - Cystic Fibrosis News Today - October 19th, 2022 [October 19th, 2022]
- FDA Expands Oversight of Cell and Gene Therapies - Pharmaceutical Technology Magazine - October 19th, 2022 [October 19th, 2022]
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 19th, 2022 [October 19th, 2022]
- Survey Reveals Most People with Spinal Muscular Atrophy Using New Gene Therapies, Focused on Treatment Pipeline - PR Newswire - October 19th, 2022 [October 19th, 2022]
- GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft To Development and Production of New AAV gene therapies - Yahoo Finance - October 19th, 2022 [October 19th, 2022]
- Gamma Biosciences, Lonza Enter Cell and Gene Therapy Alliance - Contract Pharma - October 19th, 2022 [October 19th, 2022]
- Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene... - October 19th, 2022 [October 19th, 2022]
- Gene therapy Luxturna now reimbursed in Quebec for people with previously untreatable inherited vision loss(1) - Canada NewsWire - October 19th, 2022 [October 19th, 2022]
- A sound approach for effective gene therapy delivery to brain - The Source - Washington University in St. Louis - Washington University in St. Louis - October 19th, 2022 [October 19th, 2022]
- Worldwide AAV Vector Industry Report 2022 - by Type of Therapy, Type of Gene Delivery Method Used, Target Therapeutic Area, Application Area, Scale of... - October 19th, 2022 [October 19th, 2022]
- LEXEO Therapeutics Receives Orphan Drug Designation for LX1004 from European Commission - BioSpace - October 19th, 2022 [October 19th, 2022]
- Health News Roundup: Serum Institute to produce Ebola vaccine for use in Uganda outbreak; Eli Lilly to buy gene therapy company Akouos for $487... - October 19th, 2022 [October 19th, 2022]
- New Pittsburgh biomanufacturing center to accelerate cell and gene therapy innovation - BioPharma-Reporter.com - August 30th, 2022 [August 30th, 2022]
- Trinity team's new gene therapy shows promise for treating eye condition affecting millions across the globe - Ophthalmology Times - August 30th, 2022 [August 30th, 2022]
- Ovid turns to gene therapy startup to restock drug pipeline - BioPharma Dive - August 30th, 2022 [August 30th, 2022]
- Defining the Impact of Gene Therapy - Managed Healthcare Executive - August 30th, 2022 [August 30th, 2022]
- Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy - Business Wire - August 30th, 2022 [August 30th, 2022]
- India Gene Therapy Market Research Report 2022: Prospects, Trends, Market Size and Forecasts to 2028 - ResearchAndMarkets.com - Business Wire - August 30th, 2022 [August 30th, 2022]
- Global Cell and Gene Therapy Market to Surpass US$ 90,984.2 Million by 2030 - Coherent Market Insights - PR Newswire - August 30th, 2022 [August 30th, 2022]
- Walk Again Or Stop Blindness. How Gene Therapy Is Revolutionizing Medicine - Nation World News - August 30th, 2022 [August 30th, 2022]
- Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome - BioSpace - August 30th, 2022 [August 30th, 2022]
- Porton Advanced and Kun Tuo Announce Strategic Partnership to Deepen Gene and Cell Therapy CDMO and Clinical Research Services - PR Newswire - August 30th, 2022 [August 30th, 2022]
- Gene therapies for lung cancer identified by international team of scientists - Labiotech.eu - August 30th, 2022 [August 30th, 2022]
- BioForest is Breaking Out with Innovation, Talent and Investment - BioSpace - August 30th, 2022 [August 30th, 2022]
- Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio - Yahoo Finance - August 30th, 2022 [August 30th, 2022]
- An international team sets out to cure genetic heart diseases with one shot - Freethink - August 30th, 2022 [August 30th, 2022]
- What is the difference between sickle cells and healthy RBCs? - Medical News Today - August 30th, 2022 [August 30th, 2022]
- Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials - HDBuzz - August 30th, 2022 [August 30th, 2022]
- Cell therapy weekly: Kyverna Therapeutics appoints new Senior Vice President - RegMedNet - August 30th, 2022 [August 30th, 2022]
- GICELL Announces Research Collaboration with HK inno.N for next-generation CAR-NK therapy - BioSpace - August 30th, 2022 [August 30th, 2022]
- Document: Big Pharma exec: COVID shots are 'gene therapy' - July 8th, 2022 [July 8th, 2022]
- Gene & Cell Therapy FAQs | ASGCT - American Society of Gene & Cell ... - July 8th, 2022 [July 8th, 2022]
- Gene therapy - Mayo Clinic - July 8th, 2022 [July 8th, 2022]
- FDA approves novel gene therapy to treat patients with a rare form of ... - July 8th, 2022 [July 8th, 2022]
- Adeno-Associated Virus (AAV) as a Vector for Gene Therapy - July 8th, 2022 [July 8th, 2022]
- Gene therapy: Where the action is for retinal diseases - Modern Retina - July 8th, 2022 [July 8th, 2022]
- Adverum cuts jobs, restructures to give eye gene therapy another shot - BioPharma Dive - July 8th, 2022 [July 8th, 2022]
- EditForce and Mitsubishi Tanabi Pharma to work on gene therapy for CNS - Labiotech.eu - July 8th, 2022 [July 8th, 2022]
- Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA - Business Wire - July 8th, 2022 [July 8th, 2022]
- TC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022" - PR Newswire - July 8th, 2022 [July 8th, 2022]
- AAVIATE: Gene therapy via suprachoroidal drug delivery may lower treatment burden for patients with AMD - Modern Retina - July 8th, 2022 [July 8th, 2022]
- Gene Therapy Market is Expected to Grow Revenue up to USD 20 Billion by 2028 Know More with Infinium Global Research - Digital Journal - July 8th, 2022 [July 8th, 2022]
- Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week - The Motley Fool - July 8th, 2022 [July 8th, 2022]
- PROMISING STEM CELL THERAPY IN THE MANAGEMENT OF HIV & AIDS | BTT - Dove Medical Press - July 8th, 2022 [July 8th, 2022]
- Sio Gene Therapies Inc. (NASDAQ:SIOX) Short Interest Up 33.4% in June - Defense World - July 8th, 2022 [July 8th, 2022]
- Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy -... - July 8th, 2022 [July 8th, 2022]
- A look at prospects for the US gene therapy industry - BioPharma-Reporter.com - December 27th, 2021 [December 27th, 2021]
- Taysha Gene Therapies Added to the ICE Biotechnology Index - BioSpace - December 27th, 2021 [December 27th, 2021]